APEN yields 20.00% · JEPQ yields 11.10%● Live data
📍 APEN pulled ahead of the other in Year 1
Combined, APEN + JEPQ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of APEN + JEPQ for your $10,000?
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Full APEN Calculator →The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.
Full JEPQ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.